Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Erlotinib monotherapy for advanced non-small-cell lung cancer at a medical center in northern taiwan

  • At: 2010 FIP Congress in Lisbon (Portugal)
  • Type: Poster
  • By: CHEN, Ying-Ying (Cathy General Hospital, Taipei, China Taiwan)
  • Co-author(s): Kao, Chi-Lan (Department of Pharmacy, Cathay General Hospital, TAIPEI, China Taiwan)
    Huang, Wan-Tsui (Department of Pharmacy, Cathay General Hospital, TAIPEI, China Taiwan)
    Lin, Hsi-Yen (Department of Pharmacy, Cathay General Hospital, TAIPEI, China Taiwan)
  • Abstract:

    INTRODUTION: Erlotinib is one of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) that are the standard therapies in advanced non-small-cell lung cancer (NSCLC) and is tolerable for some patients unfit for chemotherapy. AIMS: To evaluate the efficacy and tolerability of erlotinib monotherapy. METHODS: From March

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses